Clinical trials: Olanzapine, completed
Fed
Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition
The purpose of this study is to compare the single oral dose bioequivalence of olanzapine 5 mg OD tablets with Zyprexa Zydis 5 mg tablets under fed conditions and to monitor adverse events and ensure safety of subjects.
- Trial name
- NCT01503450
- Testing
- Olanzapine OD Tablets 5 mg
- Where
- India
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Schizophrenia
A First In Human Study Of PF-00184562 In Healthy Volunteers
The purposes of this study are: To determine the safety, tolerability and pharmacokinetics of single doses of PF-00184562; and To explore the exposure-response relationship of neuropsychometric and tolerability measures of…
- Trial name
- NCT00150215
- Testing
- PF-00184562, Olanzapine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Schizophrenia, Schizoaffective Disorder
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
Primary Objective: To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight gain in persons with schizophrenia who are currently taking either drug; measures of the metabolic syndrome will be…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
- Trial name
- NCT00690235
- Testing
- Pramlintide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Texas Southwestern Medical Center
Chemotherapy-induced Nausea and Vomiting
Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV
Chemotherapy-induced nausea and vomiting is a common side effect of cancer treatments, and dexamethasone offers a clear advantage over placebo for protection against chemotherapy-induced emesis in both acute and delayed phases.
- Trial name
- NCT04437017
- Testing
- Olanzapine+NK-1 RA+5-HT3 RA, Dexamethasone+NK-1 RA+5-HT3 RA
- Where
- China
- Volunteers
- 557 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Delirium, Advanced Cancer
Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer
The investigators designed a randomised multicenter clinical trial for patients with advanced cancer who are admitted to the medical oncology ward or high-care hospice.
- Trial name
- NCT01539733
- Testing
- Olanzapine, Haloperidol
- Where
- 2 sites in Netherlands
- Volunteers
- 101 people
- Sponsor
- Amsterdam UMC, location VUmc
Schizophrenia
Antipsychotic Response in Schizophrenia
Motor slowing is a hallmark, clinical sign in mental illness. Slowness can be related to a specific disease process, as in negative schizophrenia or depression or it can be the result of medications used to treat forms of mental…
- Trial name
- NCT00018668
- Testing
- Risperidone, Olanzapine, Quetiapine
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal
The purpose of this study is to investigate the mean number of schizophrenia-related hospital admissions, in adult participants with schizophrenia, occurred during 12 months before and 12 months after initiation of Paliperidone…
- Trial name
- PsiProsper (NCT03666715)
- Testing
- Oral Antipsychotics (OAPs), Paliperidone Palmitate 1-Month Formulation (PP1M)
- Where
- Portugal
- Volunteers
- 55 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Alcohol Dependence
A New Pharmacotherapy for Alcohol Dependence: Olanzapine
Craving for alcohol has been related to loss of control drinking and is a major target of biological and behavioral interventions for alcohol dependence.
- Trial name
- NCT00746785
- Testing
- 2.5 mg Olanzapine, 5mg Olanzapine
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- The Mind Research Network
Schizophrenia
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)
This study is a sequential multiple-assignment randomized trial (RCT) of antipsychotic medication treatment in first-episode schizophrenia patients in the real-world settings.Through analysis of treatment efficacy rate and…
- Trial name
- NCT03510325
- Testing
- Phase 1: Olanzapine, Phase 1: Risperidone, Phase 1: Amisulpride
- Where
- 7 sites in China
- Volunteers
- 762 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
The purpose of the protocol is to evaluate the efficacy of olanzapine compared with Aripiprazole in patients with schizophrenia.
- Trial name
- NCT00088049
- Testing
- Olanzapine, Aripiprazole
- Where
- 24 sites in United States
- Volunteers
- 560 people
- Sponsor
- Eli Lilly and Company
Weight Gain
Effects of Modafinil on Olanzapine Weight Gain
This study is designed as a 3 week, randomized, double blind, placebo controlled, trial. Olanzapine and modafinil will be titrated to 10mg and 200mg respectively.
- Trial name
- NCT00636896
- Testing
- Olanzapine plus modafinil
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neuropsychiatric Research Institute, Fargo, North Dakota
Anorexia Nervosa
Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa
Anorexia Nervosa (AN) is a serious illness associated with substantial morbidity and mortality. Weight restoration is a treatment priority, and better treatments are needed.
- Trial name
- NCT01170117
- Testing
- Olanzapine
- Where
- 5 sites in United States, Canada
- Volunteers
- 152 people
- Sponsor
- New York State Psychiatric Institute
Healthy
Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects
The main objective of this study is to determine whether administration of ketanserin (40 mg), olanzapine (10 mg), and lorazepam (2 mg) after administration of LSD (150 µg) attenuates and shortens the subjective LSD response (any…
- Trial name
- LBL (NCT05964647)
- Testing
- LSD (150 µg) + ketanserin (40 mg), LSD (150 µg) + olanzapine (10 mg), LSD (150 µg) + lorazepam (2 mg)
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Schizophrenia, Schizoaffective Disorder
Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia
The study involves a six-month, double-blind protocol during which eighty patients, across three sites around the country, will be randomly assigned to receive clozapine or olanzapine.
- Trial name
- NCT00179231
- Testing
- olanzapine vs. clozapine
- Volunteers
- 80 people
- Sponsor
- Vanderbilt University
Schizophrenia
Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)
Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by Positive symptoms (symptoms that should not be there, inability to think clearly, to distinguish reality from fantasy i.e., hearing…
- Trial name
- NCT00156091
- Testing
- Olanzapine, Asenapine
- Volunteers
- 260 people
- Sponsor
- Organon and Co
Schizophrenia
β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS
The purpose of this study is to determine whether atypical antipsychotic drugs (commonly prescribed for treating schizophrenia) induce changes in anthropometry and metabolism, including alteration in insulin sensitivity and/or…
- Trial name
- SANAT (NCT00528359)
- Testing
- quetiapine or olanzapine or risperidone or aripiprazole
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Schizophrenia
Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
Assess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic activity) in the treatment of schizophrenia.
- Trial name
- NCT00149292
- Testing
- LY2140023, olanzapine
- Where
- 2 sites in Russia
- Volunteers
- 195 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
Energy Homeostasis Under Treatment With Atypical Antipsychotics
The purpose of this study is to evaluate the effects of different atypical antipsychotics on weight changes, energy homeostasis, metabolism, energy intake as well as activity.
- Trial name
- NCT00148564
- Testing
- olanzapine, Ziprasidone
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Schizophrenia, Type 2 Diabetes Mellitus
Janssen - Glucose Regulation/Risp/Olanz
Abnormalities in peripheral glucose regulation and type 2 diabetes can occur more commonly in individuals with schizophrenia than in healthy subjects or in other psychiatric conditions.
- Trial name
- NCT00205738
- Testing
- Risperidone, Olanzapine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Bipolar Disorder
Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder
The purpose of this study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of mania in bipolar disorder in adolescents.
- Trial name
- NCT00050206
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company